Icosapent Ethyl Diminishes CV Events in Patients With Renal Disease
Results from the landmark REDUCE-IT RENAL trial were presented at the recent American Society of Nephrology Kidney Week 2020, and the results add to the mounting body of knowledge regarding the clinical impact of using icosapent ethyl in at-risk patient populations, including those with compromised renal function. Read more.

Study: Empagliflozin Associated with CV and Renal Protective Outcomes in HF Patients
In EMPEROR-Reduced clinical trial, empagliflozin decreased cardiovascular (CV) death or heart failure (HF) hospitalization, total HF hospitalizations, and reduced the progressive decline in kidney function in patients with HF and a reduced ejection fraction, with and without diabetes. In addition, empagliflozin was well tolerated in patients with chronic kidney disease. Read more.

Metoprolol Effective as Prophylaxis for Postoperative Atrial Fibrillation
In a recent publication in the BMJ, researchers investigated metoprolol compared with other treatments for prophylaxis against postoperative atrial fibrillation (POAF), a possibly fatal and morbid complication after open heart surgery. In the review, Norhayati et al searched several registries for randomized, controlled trials that evaluated metoprolol for averting the incidence of POAF after surgery against other treatments or placebo. Read more.